PaperA double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference
References (20)
A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy
Eur J Cancer
(1992)- et al.
Are all 5-HT3 receptor antagonists the same?
Eur J Cancer
(1992) - et al.
5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study
Eur J Cancer
(1993) Are granisetron and ondansetron equivalent in the clinic?
Eur J Cancer
(1992)How should nausea be assessed in patients receiving chemotherapy?
Cancer Treat Rev
(1991)- et al.
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide
N Engl J Med
(1987) Complicated problems of testicular cancer
Semin Oncol
(1988)- et al.
Combination chemotherapy with cis-dichlorodiammineplatinum (II) and adriamycin for testicular cancer refractory to vinblastine plus bleomycin
Cancer Treat Rep
(1978) Antiemetics and Cancer Chemotherapy
An outline of antiemetic treatment
Eur J Cancer Clin Oncol
(1989)
Cited by (77)
Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management
2023, Biochemical PharmacologyNeurological complications of steroids and of supportive care
2022, Neurological Complications of Systemic Cancer and Antineoplastic TherapyAntiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
2021, Cochrane Database of Systematic ReviewsFirst-generation 5-ht3 receptor antagonists
2016, Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents
- 1
The Granisetron Study Group comprises Dr T. Andre, Paris, France; Dr P. Balmes, Nîmes, France; Dr S Block, Valenciennes, France; Dr P Bouffette, Neuilly-sur-Seine, France; Dr L. Cals, La Garde-Toulon, France; Dr J. Clavreul, Saint Etienne, France; Dr T. Conroy, Vandoeuvre les Nancy, France; Dr M. Crestin, Thionville, France; Dr D. Dearnaley, Sutton, U.K.; Dr R. Despax, Toulouse, France; Prof. Dr V. Diehl, Köln, Germany; Prof. G. Falkson, Pretoria, South Africa; Dr J.-P. Fombeur, Paris, France; Dr med R. Fuchs, Eschweiler, Germany; Dr med H. Fülle, Berlin 15, Germany; Prof. J.-C. Guerin, Lyon, France; Dr P. Harper, London, U.K.; Dr med J. Hartlapp, Bonn, Germany; Dr J.-F. Heron, Caen, France; Dr J.-P. Jacquin, Saint Etienne, France; Dr med D. Kamanabrou, Münster, Germany; Dr H.J. Keizer, Leiden, The Netherlands; Dr med H.J. König, Erlangen, Germany; Dr F. Larra, Dr P. Maillart, Angers, France; Prof. Dr med H. Ludwig, Wien, Austria; Dr P.H.M. de Mulder, Nijmegen, The Netherlands; Dr H. Naman, Cannes la Bocca, France; Dr G. Netter-Pinon, Reims, France; Prof. F. Oberling, Strasbourg, France; Prof. R. Plagne, Clermont-Ferrand, France; Dr med H. Riess, Berlin 20, Germany; Dr A. Riviere, Caen, France; Dr R. Samak, Nice, France; Dr med H. Samonigg, Mrs Dr A.K. Kasparek, Graz, Austria; Prof. S. Schraub, Besançon, France; Dr J. Schuller, Wien, Austria; Prof. Dr med S. Seeber, Essen, Germany; Prof. J.J. Sotto, Grenoble, France; Prof. Dr med H. Wagner, Weiden, Germany; Dr med J. Weiss, Regensburg, Germany; Prof. Dr med M. Westerhausen, Duisberg, Germany; Dr D. Zylberait, Compiegne, France.